FMS like tyrosine kinase 3 inhibitor - Shenzhen TargetRx
Alternative Names: FLT3-Inhibitor-Shenzhen-TargetRxLatest Information Update: 26 Apr 2023
At a glance
- Originator Shenzhen TargetRx
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Haematological malignancies
Most Recent Events
- 05 Apr 2023 FMS like tyrosine kinase 3 inhibitor - Shenzhen TargetRx is available for licensing as of 05 Apr 2023. https://www.tjrbiosciences.com/en/index.php?m=content&c=index&a=lists&catid=50
- 05 Apr 2023 Preclinical trials in Haematological malignancies in China (unspecified route) (Shenzhen TargetRx pipeline, April 2023)